Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons

Clinical Immunology

Volumn 96, Issue 3, 2000, Pages 212-221

  Soulika, Athena M ^a   Khan, Mohammad M ^a   Hattori, Takashi ^a   Bowen, Frank W ^a   Richardson, Bradford A ^a   Hack, C Erik ^b   Sahu, Arvind ^a   Edmunds Jr , L Henry ^a   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

Anticoagulant; Cardiopulmonary bypass; Complement inhibitors; Compstatin; Cyclic peptides; Heparin protamine complexes; Primates

Indexed keywords

COMPLEMENT INHIBITOR; COMPSTATIN; HEPARIN; PROTAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BOLUS INJECTION; COMPLEMENT INHIBITION; INFUSION; NONHUMAN; PRIORITY JOURNAL;

EID: 0033839596     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4903     Document Type: Article

References (46)

1. Platelet function during cardiac operation: Comparison of membrane and bubble oxygenators
2. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation
3. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules
4. Upregulation of Mac-1 surface expression on neutrophils during simulated extracorporeal circulation
5. Surface-mediated defense reactions. The plasma contact activation system
6. Tissue factor is expressed on monocytes during simulated extracorporeal circulation
7. Cell-mediated immunity is depressed following cardiopulmonary bypass
8. Effect of cardiopulmonary bypass on circulating lymphocyte function
9. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass
10. Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation
11. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass
12. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass
13. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding
14. Complement activation by biomaterials
15. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction
16. Complement activation during cardiopulmonary bypass. Comparison of bubble and membrane oxygenators
17. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation
18. Evidence for complement activation by protamine-heparin interaction after cardiopulmonary bypass
19. Complement activation during cardiopulmonary bypass: Evidence for generation of C3a and C5a anaphylatoxins
20. Complement C5a-mediated myocardial ischemia and neutrophil sequestration: Two independent phenomena
21. Activation of the complement system during and after cardiopulmonary bypass surgery: Postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia
22. Complement and the damaging effects of cardiopulmonary bypass
23. C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation
24. Expression of high- and low-affinity receptors for C3a on the human mast cell line HMC-1
25. C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway
26. Role of C3 cleavage in monocyte activation during extracorporeal circulation
27. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation
28. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass
29. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin
30. Inhibition of complement activation by soluble recombinant CR1 under conditions resembling these in a cardiopulmonary circuit: Reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface
31. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo
32. A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro
33. Total complement inhibition: An effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass
34. Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment
35. The use of a heparin removal device: A valid alternative to protamine
36. Inhibition of human complement by a C3-binding peptide isolated from a phage displayed random peptide library
37. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts
38. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation
39. Large scale isolation of functionally active components of the human complement system
40. Phylogeny of the third component of complement, C3: Analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species
41. Identification of the C3b receptor-binding domain in third component of complement
42. A baboon model for hematologic studies of cardiopulmonary bypass
43. Species specificity, structural functional analysis and biotransformation studies on Compstatin, a potent complement inhibitor
44. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass
45. Acute lung injury during cardiopulmonary bypass. Are the neutrophils responsible?
46. Heparinisation, platelet activation and cardiopulmonary bypass